Equinor ASA ADR (EQNR)vsGlaxoSmithKline PLC ADR (GSK)
EQNR
Equinor ASA ADR
$36.69
-0.60%
ENERGY · Cap: $94.78B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 223% more annual revenue ($105.98B vs $32.78B). GSK leads profitability with a 17.8% profit margin vs 4.8%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 66/100 (B-).
EQNR
Buy51
out of 100
Grade: C-
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.4%
Fair Value
$54.29
Current Price
$36.69
$17.60 discount
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.4%
Generating 2.1B in free cash flow
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
4.8% margin — thin
Weak financial health signals
Revenue declined 5.1%
Earnings declined 27.3%
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EQNR
The strongest argument for EQNR centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.03 suggests the stock is reasonably priced for its growth.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth. Thin 4.8% margins leave little buffer for downturns.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
GSK carries more volatility with a beta of 0.30 — expect wider price swings.
GSK is growing revenue faster at 1.5% — sustainability is the question.
EQNR generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor OIL & GAS INTEGRATED industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GSK scores higher overall (66/100 vs 51/100), backed by strong 17.8% margins. EQNR offers better value entry with a 47.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other OIL & GAS INTEGRATED Stocks
Want to dig deeper into these stocks?